The mitochondrial gambit: Re-evaluating Antimycin A as a multi-pronged anti-cancer agent

Malignancy's profound dependence on mitochondrial metabolism establishes the organelle as a paramount therapeutic target. This review offers a comprehensive analysis of Antimycin A (AMA), a mitochondrial complex III inhibitor, framing it as a potent, multi-pronged anti-cancer agent. While AMA primarily disrupts oxidative phosphorylation (OXPHOS)—triggering a cascade of adenosine triphosphate (ATP) depletion, massive reactive oxygen species (ROS) surges, and subsequent apoptosis—its therapeutic potential extends significantly to non-canonical functions crucial for countering adaptive resilience. Specifically, AMA acts as a Bcl-2 homology 3 (BH3) mimetic by directly inhibiting B-cell lymphoma-extra large (Bcl-xL) and induces ROS-mediated proteasomal degradation of the c-Myc oncoprotein. Additionally, it effectively targets chemoresistant cancer stem cells (CSCs) by suppressing Wnt/β-catenin signaling. By juxtaposing its powerful anti-neoplastic activities with pharmacological limitations such as systemic toxicity, this paper evaluates ongoing strategies to develop safer, clinically viable analogues. Ultimately, AMA is presented not merely as an experimental tool, but as a pivotal lead compound whose mechanisms illuminate critical vulnerabilities in cancer, providing a strategic blueprint for the future of mitochondria-targeted oncology.